Article

Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival

University of South Florida, Tampa, Florida, United States
Cancer Research (Impact Factor: 9.28). 07/2006; 66(11):5542-8. DOI: 10.1158/0008-5472.CAN-05-4620
Source: PubMed

ABSTRACT Mutations of the epidermal growth factor receptor (EGFR) selectively activate Akt and signal transducer and activator of transcription (STAT) pathways that are important in lung cancer cell survival. Src family kinases can cooperate with receptor tyrosine kinases to signal through downstream molecules, such as phosphatidylinositol 3-kinase/PTEN/Akt and STATs. Based on the importance of EGFR signaling in lung cancer, the known cooperation between EGFR and Src proteins, and evidence of elevated Src activity in human lung cancers, we evaluated the effectiveness of a novel orally bioavailable Src inhibitor dasatinib (BMS-324825) in lung cancer cell lines with defined EGFR status. Here, we show that cell fate (death versus growth arrest) in lung cancer cells exposed to dasatinib is dependent on EGFR status. In cells with EGFR mutation that are dependent on EGFR for survival, dasatinib reduces cell viability through the induction of apoptosis while having minimal apoptotic effect on cell lines with wild-type (WT) EGFR. The induction of apoptosis in these EGFR-mutant cell lines corresponds to down-regulation of activated Akt and STAT3 survival proteins. In cell lines with WT or resistant EGFR mutation that are not sensitive to EGFR inhibition, dasatinib induces a G(1) cell cycle arrest with associated changes in cyclin D and p27 proteins, inhibits activated FAK, and prevents tumor cell invasion. Our results show that dasatinib could be effective therapy for patients with lung cancers through disruption of cell growth, survival, and tumor invasion. Our results suggest EGFR status is important in deciding cell fate in response to dasatinib.

0 Followers
 · 
136 Views
  • Source
    • "Shown are representative blots of three independent experiments. cancer cells posses other active pro-survival signaling pathways such as EGFR, STAT3 and c-Met [17] [30] [42] [44] [45]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Although inhibition of epidermal growth factor receptor (EGFR) signaling during radiation led to improvement of tumor control and survival, novel strategies are needed to further improve the outcome of patients with locally advanced head and neck carcinoma. Because EGFR is known to interact with c-Src kinases, the present study investigated dasatinib (BMS-354825), an inhibitor of c-Src kinases, for its efficacy in enhancing radiosensitivity of human head and neck squamous cell carcinomas (HNSCC) in vitro and examined the underlying mechanisms for this effect.
    Radiotherapy and Oncology 09/2012; 105(2). DOI:10.1016/j.radonc.2012.08.010 · 4.86 Impact Factor
  • Source
    • "In the absence of any known naturally occurring activating mutations in the STAT3 gene, aberrant STAT3 activation is predominantly due either to persistent Y phosphorylation signals emanating from dysregulated upstream tyrosine kinases, such as hyperactive growth factor receptors or non-receptor tyrosine kinases, including Src or JAKs, or to the over-expression of stimulatory ligands, such as EGF or IL- 6 [17]. These molecular events are exemplified by the constitutive activation of STAT3 mediated by the persistent stimulation of the IL-6/gp130 and the JAK/STAT pathways in multiple myeloma (MM), large granular lymphocyte (LGL) leukemia, and prostate cancer [18] [19] [20], as well as by elevated EGFR-mediated signaling and the activity of Src and JAKs in breast cancer, prostate cancer, non-small cell lung cancer (NSCLC), melanoma, pancreatic cancer, and head and neck squamous carcinoma (HNSCC) cells [21] [22] [23] [24] [25] [26] [27] [28] [29]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The signal transducers and activators of transcription (STATs) include a class of cytoplasmic signaling proteins whose role in the regulation of cell growth and survival is mediated by phosphorylation of a critical tyrosine residue within the STAT protein. This occurs in response to cytokines and growth factors modulating the expression of specific target genes. In particular, phosphorylation induces STAT:STAT dimer formation between two monomers, via reciprocal phosphoTyr (pTyr)-SH2 domain interactions. To date, seven members of the STAT family, all with different roles, have been identified in mammals. After dimerization, phosphorylated STATs enter the nucleus and, working co-ordinately with other transcriptional co-activators and transcription factors, induce increased transcriptional initiation. In healthy human and animal cells, ligand-dependent activation of STATs is a transient process, lasting for several minutes to several hours. In contrast, in many cancerous cell lines and tumors, where growth factor dysregulation is frequently at the heart of cellular transformation, the STAT proteins (in particular STAT1, 3 and 5) are persistently tyrosine-phosphorylated or activated; abnormal levels of STAT3 activation have been observed in breast, ovarian, prostate, hematological and head and neck cancer cell lines. Thus, in this review, we examine the most important classes of agents designed to disrupt STAT3 signaling, with particular regard to STAT3 dimerization inhibitors, which could play a significant role in the future of cancer and adjuvant cancer therapies.
    Current Medicinal Chemistry 06/2011; 18(16):2359-75. DOI:10.2174/092986711795843218 · 3.85 Impact Factor
  • Source
    • "Similarly, in lung cancer cells, dasatinib seemed to inhibit EGFR-dependent cell lines preferentially, whereas having a minimal effect on their wild-type EGFR-expressing counterparts. Moreover, dasatinib inhibited cell growth by promoting G 1 /S cell cycle arrest, with associated changes in the levels of cyclin D and p27 [49]. Dasatinib can also reduce metastatic disease and osteoclast-mediated bone resorption. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The SRC family kinases are the largest family of nonreceptor tyrosine kinases and one of the best-studied targets for cancer therapy. SRC, arguably the oldest oncogene, has been implicated in pathways regulating proliferation, angiogenesis, invasion and metastasis, and bone metabolism. More recently, researchers have proposed that the transforming ability of SRC is linked to its ability to activate key signaling molecules in these pathways, rather than through direct activity. It has been hypothesized that blocking SRC activation may inhibit these pathways, resulting in antitumor activity. However, successfully targeting SRC in a clinical setting remains a challenge, and SRC inhibitors have only recently begun to move through clinical development. Preclinical studies have identified specific molecular "subgroups" and histologies that may be more sensitive to SRC inhibition. In addition, other studies have demonstrated synergistic interactions between SRC inhibitors and other targeted therapies and cytotoxics. In this review, we summarize SRC biology and how it has been applied to the clinical development of SRC inhibitors. The status of SRC inhibitors, including dasatinib, saracatinib, and bosutinib, which are in phase 1, 2, and 3 trials, is highlighted.
    Neoplasia (New York, N.Y.) 08/2010; 12(8):599-607. DOI:10.1593/neo.10328 · 5.40 Impact Factor
Show more

Preview

Download
4 Downloads